# A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer

> **NCT01095848** · PHASE1 · COMPLETED · sponsor: **ImmunoVaccine Technologies, Inc. (IMV Inc.)** · enrollment: 23 (actual)

## Conditions studied

- Ovarian Neoplasms
- Breast Neoplasms
- Prostatic Neoplasms

## Interventions

- **BIOLOGICAL:** DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG

## Key facts

- **NCT ID:** NCT01095848
- **Lead sponsor:** ImmunoVaccine Technologies, Inc. (IMV Inc.)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-04
- **Final completion:** 2011-11
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2015-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01095848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01095848, "A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01095848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*